ARCH Venture Fund XII declares 25.6% of newly listed City Therapeutics

ARCH Venture Fund XII, a venture capital fund, holds 25.6% of City Therapeutics after its stock market debut and says it holds the shares for investment.

The filing

13D
25.6%
Of the shares
$293.84M
Value
Active
Investor
C
City Therapeutics, Inc. Common Stock
Holds 13,692,507 shares

Stated purpose

ARCH Venture Fund XII says it holds City Therapeutics shares for investment and may buy or sell more depending on market conditions, with no present plans for other changes.
Declared to the SEC, the US stock market watchdog (Schedule 13D), after the 5% threshold was crossed on October 19, filed on October 26.

AI analysis

Oct 26
With TrueWallet Pro
What this filing changes for the stock, what the fund wants, and what it does not say. Upgrade to Pro from the TrueWallet app.

The whole feed is waiting

Sign in to read every post and follow wallets.
Sign in